Evidence map›Paper›PMID 40261144›Full record

ReviewJournal of medicinal chemistry2025

Switching It up with New KRAS Inhibitors.

Alex G Waterson

Abstract readReview
In one paragraph

Review in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Alex G WatersonDepartments of Pharmacology and Chemistry, Vanderbilt University School of Medicine, 2220 Pierce Avenue, Nashville, Tennessee 37232, United States.ORCID 0000-0002-0153-5723

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alongside significant recent advancements in drugging an historically notorious oncogene, scientists continue to uncover new ways to target KRAS. This viewpoint summarizes the newly reported discovery of a novel chemical template that features the ability to tailor inhibition to different activation states of nucleotide-bound KRAS from the same scaffold.

Indexed as

Antineoplastic AgentsProto-Oncogene Proteins p21(ras)HumansAntineoplastic AgentsKRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID40261144
PMCPMC12067428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.